Has Lin Soe received payments from drug or device companies?

Yes. Drug and device makers reported $14,188 in general payments to Lin Soe across 703 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lin Soe did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lin Soe come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lin Soe

Hematology & Oncology · San Luis Obispo, CANPI 1467524900

Payments from drug & device makers

$14,188in general payments, 2019–2025

Across 703 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$966
Johnson & Johnson$961
AstraZeneca$857
Novartis$697
Merck$688
Pfizer$685
plus $9K from 54 others

What the payments were for

Food & beverage$13,93598%
Education$2532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	67	$966
Johnson & Johnson(2 entities)	46	$961
AstraZeneca(2 entities)	41	$857
Novartis	39	$697
Merck	34	$688
Pfizer	51	$685
Daiichi Sankyo Inc.	33	$624
Genentech USA, Inc.	25	$615
Bristol Myers Squibb	24	$464
Exelixis Inc.	18	$462
GSK	21	$418
Astellas Pharma US Inc	23	$409
Seagen Inc.	21	$399
Amgen	15	$376
Eisai Inc.	18	$369
Takeda Pharmaceuticals U.S.A., Inc.	15	$340
Lilly USA, LLC	8	$301
Blueprint Medicines Corporation	7	$288
ADC Therapeutics America, Inc.	6	$266
AbbVie	13	$255
Pharmaessentia USA Corporation	5	$208
Sobi, Inc	8	$176
Array Biopharma Inc	9	$160
Rigel Pharmaceuticals, Inc.	9	$158
Puma Biotechnology, Inc.	8	$153
Pharmacyclics LLC, An Abbvie Company	6	$151
Jazz Pharmaceuticals Inc.	7	$144
Bayer	7	$136
Sanofi	7	$113
Incyte Corporation	6	$111
Karyopharm Therapeutics Inc.	4	$109
Gilead(2 entities)	5	$108
Regeneron Healthcare Solutions, Inc.	4	$105
EMD Serono, Inc.	5	$99
Taiho Oncology, Inc.	4	$98
Syndax Pharmaceuticals, Inc.	4	$95
Ipsen Biopharmaceuticals, Inc	5	$93
Stemline Therapeutics Inc.	4	$93
Agios Pharmaceuticals, Inc.	5	$85
Janssen Scientific Affairs, LLC	1	$83
Boehringer Ingelheim	4	$82
Apellis Pharmaceuticals, Inc.	4	$76
Mirati Therapeutics, Inc.	4	$67
AVEO Pharmaceuticals, Inc.	4	$64
Alnylam Pharmaceuticals Inc.	4	$59
Servier Pharmaceuticals LLC	3	$55
Genmab U.S., Inc.	2	$55
Menarini Silicon Biosystems, Inc.	2	$47
Pharmacosmos Therapeutics Inc.	2	$45
Beone Medicines USA, Inc.	2	$44
Accord Healthcare, Inc.	2	$44
Secura Bio, Inc.	1	$42
Springworks Therapeutics, Inc.	2	$39
Tersera Therapeutics LLC	1	$38
Tempus AI, Inc	2	$38
Coherus Oncology, Inc.	1	$38
Geron Corporation	2	$37
Clovis Oncology, Inc.	2	$37
Recordati_rare_diseases_inc.	2	$36
Immunogen, Inc.	2	$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,188 in reported general payments places this provider in the 55th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Medicare billing

Part B allowed, 2024

$276,327

Medicare patients

578

Services billed

1,937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Anastrozole	51	$932
Hydroxyurea	22	$635
Ondansetron OdtOndansetron	11	$381
Dexamethasone	14	$216

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in San Luis Obispo

Alain AlgaziSan Francisco$119.2M
David BerzLos Angeles$43.3M
Jonathan GoldmanSanta Monica$35.7M
Omid HamidSanta Monica$23.7M
Nicholas McAndrewLos Angeles$22.9M
Aditya BardiaSanta Monica$22.1M
Joseph TuscanoSacramento$20.4M
Zev WainbergSanta Monica$19.3M
Caitlin CostelloSan Diego$16.9M
Rana McKaySan Diego$15.3M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →